Quality System
Lixin Honor:

Lixin Pharmaceutical was approved by U.S. Food and Drug Administration (FDA) in 2010, and had a review with zero defect in 2015.

Lixin Pharmaceutical was approved by European Directorate for the Quality of Medicines (EDQM), European Medicines Agency (EMA) in Oct, 2016.

A number of products receive certificates of GMP by China Food and Drug Administration (NMPA)

About Us
Since established in 2000, Suzhou Lixin Pharmaceutical CO., Ltd. has been aimed at develop the global normative dominant market of APIs and advanced intermediates, driven by technological innovation, taken the path of sustainable development, and gradually form a raw materials products system including anti-tumor, cardiovascular, anti-platelet and treatment of senile dementia and other areas. Lixin Pharmaceutical has already been the high-quality supplier of many global pharmaceutical companies, and also established long-term relationship with a number of well-known domestic and foreign pharmaceutical companies to achieve win-win cooperation.
  R&D
NEWS    LiXin News
Image

我公司氫氯噻嗪、吲達帕胺通過CEP認證

我公司氫氯噻嗪、吲達帕胺通過CEP認證...

Image

蘇州立新制藥有限公司抗腫瘤及心血管原料藥技改項目 自查評估報告公示

蘇州立新制藥有限公司抗腫瘤及心血管原料藥技改項目 自查評估報告…...

Image

立新制藥順利通過第二次FDA檢查

立新制藥順利通過第二次FDA檢查...

换人妻好紧三p_两个男人添我下面试看十分钟_国产午夜无码精品免费看_chinese中国女人高潮